USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Péter Bacsur  ¹     Mária Matuz  ²     Tamás Resál     Pal Miheller  ³     Tamás Szamosi  ⁴     Eszter Schäfer     Patrícia Sarlós  ⁵     Ákos Iliás  ⁶     Kata Szántó     Mariann Rutka     Anita Balint     Ágnes Milassin     Anna Fabian     Renáta Bor     Szepes Zoltán     Tamás Molnár     Klaudia Farkas    
¹ Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary
² Faculty of Pharmacy, University of Szeged, Szeged, Hungary
³ Semmelweis University, Budapest, Hungary
⁴ Military Hospital - State Health Centre, Budapest, Hungary
⁵ University of Pécs, Pécs, Hungary
⁶ Faculty of Medicine, Semmelweis University, Budapest, Hungary

Session
Investigator studies in IBD I (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)